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Abstract
This study was conducted to determine the feasibility of detecting BRAF(V600E)
circulating tumor DNA (ctDNA) in the plasma of patients with thyroid nodules, with the
goal of distinguishing between benign and malignant nodules. Plasma samples from
patients undergoing thyroid surgery for thyroid nodules were obtained prospectively preoperatively and one month post-operatively, and quantitative-PCR was used determine
the presence of BRAF(V600E) ctDNA. These were compared to formalin fixed paraffin
embedded samples from the index nodule. Thirty-eight pairs of preoperative and
postoperative plasma samples were collected and analyzed. 6/18 (33.3%) patients with
classical PTC and 0/8 (0%) patients with nodular hyperplasia had detectable levels of
BRAF(V600E) ctDNA pre-operatively, thus BRAF(V600E) ctDNA was able to
distinguish between benign and malignant nodules (p < 0.05). The levels of all samples
with detectable BRAF(V600E) ctDNA pre-operatively declined post-operatively (p <
0.05). BRAF(V600E) ctDNA can be detected in plasma. Post-operative drop of
BRAF(V600E) ctDNA in all cases suggests its utility as a tumor marker.

Keywords
Circulating tumor DNA, cell free DNA, ctDNA, thyroid cancer, thyroid nodule,
BRAF(V600E)
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1.

Introduction

There is an increasing incidence of thyroid cancer in developed countries, with
approximately 75% of these cases occurring in women. Although approximately 50% of
thyroid glands have thyroid nodules when examined at autopsy, during surgery or by
ultrasound, approximately two-thirds of these are benign.1 Up to 35% of thyroid glands
removed at autopsy or surgically have clinically unimportant thyroid cancers, primarily
papillary thyroid cancers (PTC) less than 1.0 cm.2,3 It is the most common endocrine
malignancy worldwide and tenth most common cancer in Canada.4 In Canada, from 1986
to 2010, the age standardized incidence rate (ASIR) for thyroid cancer increased from 2.0
to 5.9 per 100,000 in males and from 5.2 to 20.6 per 100,000 in females (Figure 1).5
There was a 6.3% per year increase in incidence of thyroid cancer in males from 2001 to
2010 and 4.4% per year increase in incidence of thyroid cancer in females from 2005 –
2010.

In the U.S. there has been a steady rise in the rate of primary thyroid malignancies with
37,200 new cases diagnosed in 2009, 48,000 new cases diagnosed in 2011 and
approximately 60,220 new cases diagnosed in 2013.6-9 There has been increased
utilization of fine needle aspirate biopsies (FNAB) in managing these thyroid nodules and
in 2011 an estimated 450,000 thyroid fine needle aspirate biopsies (FNABs) were
performed.9,10 Increased incidence of thyroid cancer has been largely attributed to
increased use of ultrasound which can detect sub-centimeter thyroid nodules and routine
use of FNAB as first line replacing nuclear medicine scans.4,10,11 The majority of these
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new case are very early stage disease, with 68% being T1 cancers of 2.0 cm or less (39%
less than 1.0 cm and 29% between 1.0 to 2 cm).6,10,12 Other hypotheses for this dramatic
rise in incidence include increased exposure to medical radiation, increased dietary iodine
intake, and increased prevalence of chronic autoimmune thyroiditis.4,11 Despite the
increasing incidence of thyroid cancer, mortality rates have not changed over the past
decade, implying that the majority of these newly identified cases are low risk disease.6,10
Thyroid neoplasms include thyroid adenoma, well differentiated thyroid cancer, poorly
differentiated thyroid cancer, anaplastic (undifferentiated) thyroid cancer and medullary
cancer (Figure 2)13. Well differentiated thyroid cancer is by far the most common type of
thyroid cancer with PTC being the most common in about 85% of the cases, follicular
thyroid cancer (FTC) in about 10% of the cases and finally Hurthle cell or oxyphil tumors
in 3% of the cases (Table 1).14,15

1.1 Contemporary Thyroid Nodule Management

According to American Thyroid Association guideline, a detailed history and physical is
the first step in evaluating a patient presenting with thyroid nodule (Figure 3).16 Risk
factors for thyroid cancer include family history of thyroid cancer in one or more first
degree relatives, certain thyroid cancer syndromes (e.g. Cowden’s syndrome, Familial
Polyposis, Carney Complex, Multiple Endocrine Neoplasia 2, Werner syndrome) in first
degree relative, and previous exposure of neck to ionizing radiation. Thyroid Stimulating
Hormone (TSH) levels should be measured, and in patients with low TSH, a radioactive
iodine scan should be done to assess for a hyper-functioning nodule. Patients with hyper-
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functioning nodules are very unlikely to have a thyroid cancer (~1%). If the patient has a
normal or high TSH, ultrasound assessment of the thyroid bed is essential to measure the
nodule size and characteristics. Although no single sonographic feature or combination of
features is highly specific or sensitive in diagnosing nodules to be malignant, certain
ultrasound characteristics, such as microcalcifications, hypoechogenicity compared to the
thyroid bed, increased nodular vascularity, infiltrative margins (absent halo) or taller than
wide on transverse view, can be helpful in identifying high risk nodules.17-22 In contrast,
spongiform and purely cystic nodules are likely to be benign nodules.18,23 Ultrasound is
also helpful in assessing the presence of any cervical lymphadenopathy in the setting of
thyroid cancer, as it identifies suspicious cervical lymphadenopathy in 20 – 31% of the
cases.24-27 For those patients who do not fall into the high risk category, thyroid nodules
greater than 1 cm or those which are increasing in size (20% increase in nodule diameter
with a minimum increase in two or more dimensions of at least 2 mm or 50% increase in
nodule volume) should be biopsied with a fine needle aspirate biopsy (FNAB).16,28-30
Nodules that are greater than 4 cm should be removed surgically, as the diagnostic
sensitivity decreases with increasing size.31

FNAB reports are based on the Bethesda system, where the FNAB specimen is assessed
by a cytopathologist and the likelihood of malignancy is reported. The results are divided
into 5 categories (Table 2).32 As evident from the malignancy risk, FNAB is extremely
useful for the low and high risk categories, but it does poorly in the
indeterminate/intermediate category. Thus, patients may undergo diagnostic hemithyroidectomy, surveillance ultrasounds and FNAB, which results in significant patient
discomfort and increased cost to the health care system.
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1.2 Risks of Thyroid Surgery

As previously noted, diagnostic hemi-thyroidectomy is recommended for those with
FNAB reported as indeterminate/intermediate risk of cancer. Thyroid surgery is
associated with the risks of general anesthetic, bleeding, infection, transient or permanent
hypothyroidism, transient or permanent hypocalcemia (if total thyroidectomy), and injury
to both superior and recurrent laryngeal nerve resulting in voice alteration, dysphagia and
potential airway compromise. Injury to the superior laryngeal nerve can result in inability
to raise the pitch of the voice and altered sensation of the hemi-larynx. Recurrent
laryngeal injury is more severe, as it results in a paralyzed vocal cord on the affected side,
thus resulting in a breathy voice. The overall incidence of this complication is 2 –
10%.33,34 Although the risks are generally lower in the hands of high volume thyroid
surgeons, 50% of thyroid surgeries in the U.S. are performed by low volume surgeons
who do less than 5 thyroidectomies per year.35

Thus, by improving the accuracy of diagnosis and decreasing the risk of malignancy in
the indeterminate/intermediate category of FNAB, diagnostic surgeries can be avoided.
This has the potential to decrease costs in an already strained Canadian healthcare
system.
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1.3 Thyroid Cancer Follow up

Currently thyroid cancer surveillance is done by stimulated and unstimulated
thyroglobulin levels and radioactive I131 scan in select cases that receive adjuvant
radioactive iodine.16 Twenty-three to 29% of patients with well differentiated thyroid
cancers have antithyroglobulin antibodies, thus making surveillance of thyroid cancer
recurrence difficult.36-39 Moreover, 12% of cases are thyroglobulin negative
pre-operatively with the entire gland in situ, highlighting the imperfections of
thyroglobulin for monitoring disease burden.40 Thus a new test that can aid in thyroid
cancer surveillance would be highly beneficial.

1.4 Genetics of Thyroid Cancer

Three distinct pathways are proposed for neoplastic transformation and proliferation of
thyroid follicular cells: hyper-functioning follicular thyroid adenoma, FTC and PTC (see
Figure 4).15 Most poorly differentiated and undifferentiated thyroid carcinomas are
thought to arise from pre-existing well-differentiated thyroid carcinomas through
additional genetic events. Several genes have been implicated in the pathogenesis of
thyroid cancer which include: point mutations in BRAF, RAS, CTNNB1, and TP53; and
gene rearrangement in BRAF, RET, NTRK1, and PPARG (Table 3).15 BRAF(V600E)
mutation is the most commonly encountered point mutation in PTCs and has been
reported in varying percentages from 29 – 69%.41-49 A recent report by The Cancer
Genome Atlas Research Network (TCGA) has further clarified the genomic landscape of
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PTCs.41 Majority of the PTCs appear to be driven by a single mutually exclusive point
mutation (most commonly either BRAF or RAS) or gene fusions. Additionally, PTCs can
be subclassified into classical V600E BRAF-like PTCs and RAS-like PTCs. Thyroid
samples were ranked by BRAF(V600E) – RAS score (BRS), with BRS being strongly
associated with driver mutation status, thyroid differentiation score, histology and
follicular fraction. Differential activation of molecular pathways depending on the driver
mutations was thought to be the underlying mechanism – classical PTCs were more
BRAF(V600E)-like on the thyroid differentiation score whereas the histological variants
of follicular, tall cell and other variants of PTCs were more RAS-like on the thyroid
differentiation score.

Thus a test that can help differentiate between a malignant thyroid nodule from a benign
one, predict tumor aggressiveness and facilitate cancer surveillance would be extremely
helpful. Currently, there are two proprietary tests that are available in United States
targeting the intermediate and indeterminate Bethesda categories through molecular
testing of additional FNA samples– Afirma and Thyroseq v2. Afirma gene expression
classifier developed by Veracyte Inc. (South San Francisco, CA), costs USD $4200 per
nodule and requires samples to be sent to a central facility. This is a “rule out” test with
preliminary studies suggesting a high negative predictive value of 94 – 95%, but low
positive predictive value of 15 – 37% in the indeterminate category.50,51 However, more
recent follow up studies suggest that the test is less accurate than originally reported.51-59
Ongoing surveillance with US and US-FNAB is still recommended if the test is negative.
Thyroseq v2 offered by CBLPATH and developed by the University of Pittsburg Medical

7

Center Division of Molecular and Genomic Pathology costs USD $2250 and requires
samples to be sent to a central facility. Nikiforov published a recent series of 143 patients
with FNAB diagnosis of follicular neoplasm (FN)/suspicious for follicular neoplasm
(SFN).60 Thyroseq v2 has been termed as “rule in” test with a high negative predictive
value of 96% and a positive predictive value of 83%. Both of these tests are currently not
available in Canada, require shipping the samples to a central facility and cannot be used
for thyroid cancer surveillance. Typically, additional FNA samples are needed to carry
out these tests, which can cause additional patient pain and anxiety.

We propose an alternative test to assess the presence of thyroid cancer using circulating
tumor DNA (ctDNA) in plasma samples. Plasma samples provide several advantages
over the traditional FNAB or Affirma – there would be significantly less discomfort to
the patient with a routine blood draw rather than ultrasound guided FNAB, plasma
samples are easy to handle and most tertiary care hospitals already have a polymerase
chain reaction (PCR) machines available.

1.5 Circulating Tumor DNA (ctDNA)

Cell-free nucleic acids (cfDNA) in human blood were first described in 1948 by Mandel
and Metais.61 There was very little enthusiasm in cfDNA until in 1994 it was discovered
that mutated RAS gene fragments in blood were from cancer cells.62 With recent
advances in molecular technology there has been great interest in cfNA in detection and
surveillance of cancer (Figure 5 and Figure 6).
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cfNA is comprised of DNA, RNA and microRNAs in the plasma or serum and can be
used as “liquid biopsy”, circumventing the need for tissue biopsy and facilitating
surveillance of cancer. ctDNA can be released by apoptotic and necrotic cancer cells,
actively secreted by tumor cells or after tumor cells are processed by macrophages
(Figure 7).63-65 Although the half-life of the ctDNA is variable and estimated to be
between 15 minutes to several hours66,67, there is constant release of tumor ctDNA. Diehl
et al. estimated that for a tumor that weighs 100g (approximately 3 x 1010 tumor cells), up
to 3.3% of tumor DNA enters plasma each day.68

Analysis of ctDNA has several advantages. These include characterization of molecular
profiles when tissue is not available, reflects tumor heterogeneity, allows monitoring of
response to therapy, detect residual disease following therapy, assesses tumor evolution
with therapy and finally allows analysis of pharmacodynamics of the chemotherapy drugs
(Table 4). Thus genetic alterations in ctDNA are better poised as biomarkers than
conventional proteins such as CEA or CA19-9, which are expressed both in tumor and
normal cells.

In other cancers, ctDNA levels have been shown to be higher in patients with cancer66,69
and decrease after surgery70. However they can also be elevated in non-cancer patients
with some overlap in the ranges.66,71 Importantly, there can be considerable variation
amongst different tumor types.69 This underscores the importance of studying ctDNA in
each specific cancer.
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ctDNA, which includes coding and noncoding genomic DNA, does allow for monitoring
of tumor specific changes and allows detection of genetic and epigenetic changes within
the patient. Microsatellite instability, loss of heterozygosity, mutations, polymorphisms,
methylation and integrity can be assessed in ctDNA samples. These have been
extensively studied in various tumor types including bladder, breast, cervical, colorectal,
hepatocellular carcinoma, lung, non-hodgkin’s lymphoma, melanoma, ovarian, pancreatic
and prostate cancers.reviewed in 72

ctDNA has been used for prognostication purposes. KRAS hotspot mutations and
CDKN2A hypermethylation in patients with colorectal cancer was investigated by
Lecomte et al. The 2-year survival rate was 100% in patients who did not KRAS
mutations or CDKN2A gene promoter hypermethylation.73 In addition patients who had
residual detectable ctDNA after surgery relapsed within 1 year.68

Tumor heterogeneity is a recognized pitfall of tumor tissue sampling, with detection of
ctDNA providing an avenue to potentially mitigate this. Kuo et al. showed that ctDNA
provides a better representation of the overall cancer than focal primary site tumor
biopsies.74

ctDNA can be used as a predictive biomarker to monitor response to therapy as well as
for prognostication. Tie et al. found that in metastatic colorectal cancer, ctDNA was
detectable in plasma and early changes in ctDNA during chemotherapy predicted the
radiologic response, which was seen later in the time course.75 Bettegowda et al. in 31
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patients with colorectal cancer found 70 somatic mutations that were not detected in
tumor or plasma before initiation of EGFR blockade.69 They also found that colorectal
tumor patients who had metastatic disease with low levels of ctDNA lived significantly
longer than patients with higher levels. A similar association has been reported in breast
cancer patients as well.76

Following the amount of ctDNA and the genetic alterations of ctDNA over time can
enable real time surveillance of cancer, early detection and guide therapeutic
management. Additionally, ctDNA can theoretically account for genetic heterogeneity
within the tumor. Other important advantage is that plasma is easier to collect and
process, and health laboratories in most hospitals have readily available technology for
molecular processing. Role of ctDNA has not been thoroughly investigated in thyroid
cancer.
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1.6 Hypothesis

PTC nodules harboring BRAF(V600E) ctDNA will shed BRAF(V600E) ctDNA in blood.
Thus BRAF(V600E) ctDNA can be used to differentiate between PTC and benign
nodules.

1.7 Objectives

1. Detect BRAF(V600E) ctDNA in preoperative plasma samples of patients undergoing
thyroid surgery for nodular thyroid disease.
2. Compare BRAF(V600E) ctDNA levels in preoperative and postoperative plasma
samples of patients undergoing thyroid surgery for nodular thyroid disease.
3. Determine concordance of BRAF(V600E) between preoperative plasma samples and
the corresponding FFPE sample of index thyroid nodule.
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2

Methods

2.1 Patient Recruitment

Patients referred to the Otolaryngology – Head and Neck Surgery Clinic at the London
Health Sciences Centre for thyroid nodules from April 2014 to March 2015 were
approached for participation in the study.

2.1.1

Eligibility

Inclusion criteria included patients over the age of 18 and those scheduled to undergo
partial or total thyroidectomy for their thyroid nodules.

Exclusion criteria included previous cancer that is known to be positive for
BRAF(V600E) mutation (such as melanoma, lung cancer and colon cancer).

2.1.2

Ethics Board Approval

Patients were recruited as per the London Health Sciences Center (LHSC) Research
Ethics Board Approval (see Appendix D, Appendix E, Appendix F and Appendix G).
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2.1.3

Sources of Funding

This study was supported by a grant from The Thyroid Cancer Foundation – London
Chapter and internal funding from the Department of Otolaryngology – Head and Neck
Surgery.

2.2 Specimen Collection

Patient’s blood was collected in 5 mL EDTA coated blood collection tubes by the LHSC
lab. This was then promptly transferred to our lab and blood was processed. Blood was
separated into plasma and red blood cells by centrifuging at 1000g for 10 minutes at
room temperature. Plasma was then pipetted out and aliquoted in 1 ml cryovials and
frozen at -80°C.

2.3 Isolation of Circulating Nucleic Acids

Previously processed and frozen 1 ml aliquots of plasma samples were thawed and
equilibrated to room temperature. QIAamp circulating nucleic acid kit (Cat no. 55114)
was used using a vacuum manifold for isolation of circulating nucleic acids. 100 ul of
Proteinase K was pipetted in a 50 ml centrifuge tube. 1 ml of plasma was added into the
tube. 0.8 ml of Buffer ACL (containing 1 ug carrier RNA) was added and the mixture
was vortexed and incubated at 60°C for 30 min. 1.8 ml of Buffer ACB was added to the
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lysate and vortexed. The lysate-Buffer ACB mixture was incubated on ice for 5 mins.
The mixture was then applied into the QIAamp Mini Column placed in the vacuum
manifold. Once the mixture was completely through the column, 600 ul of Buffer ACW1
was then applied. Once Buffer ACW1 was completely through the column, 750 ul of
Buffer ACW2 was then applied. Once Buffer ACW2 was completely through the
column, 750 ul of ethanol was then applied. The column was then removed from the
vacuum manifold and placed in a collection tube and centrifuged at 14,000 rpm for 3
min. The column was placed in a new collection tube and incubated at 56°C for 10 min to
dry the membrane. The column was then placed in new elution tube and 100 ul of Buffer
AVE was applied to the center of the membrane and incubated at room temperature for 3
mins. Thereafter, the column was centrifuged for 1 min at 21,000g to elute the nucleic
acids. Concentration of the nucleic acids was measured using a NanoDrop
spectrophotometer.

2.4 Isolation Of Nucleic Acids From Formalin Fixed Paraffin
Embedded (FFPE) Samples

Index thyroid nodules were identified on the paraffin embedded post-surgical specimens.
Cores were obtained and nucleic acids were extracted using the QIAamp DNA FFPE
tissue kit (Cat no. 56404). 1 ml xylene was added to the core FFPE specimens and the
microcentrifuge tube was vortexed and then centrifuges at 14,000 rpm for 2 min. The
supernatant was carefully removed and 1 ml of ethanol was added to the pellet. The
mixture was vortexed and then centrifuged at 21,000g for 2 min. The tube was then
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incubated at 37°C until the residual ethanol had evaporated. The pellet was then
resuspended in 180 ul Buffer ATL followed by addition of 20 ul of proteinase K and
mixed by vortexing. The samples were then incubated at 56°C for at least 1 hr (or until
the sample had been completely lysed). Thereafter the samples were incubated at 90°C
for 1 hr. The samples were then briefly centrifuged and 200 ul of Buffer AL was added
followed by addition of 200 ul of ethanol. After brief centrifugation, the entire lysate was
transferred to a QIAamp MinElute column and centrifuged at 7,000g for 1 min. The
column was placed in a clean collection tube and centrifuged at 21,000g for 3 min. The
column was placed in a clean microcentrifuge tube and 100 ul of Buffer ATE was applied
for elution and it was incubated for 5 min. The column was then centrifuged at 21,000g
for 1 min. Concentration of the nucleic acid was measured using a NanoDrop
spectrophotometer.

2.5 Quantitative Polymerase Chain Reaction (qPCR) for
BRAF(V600E)

The Qiagen QuantiTect Multiplex PCR Kit (Cat No. 204543) was used for qPCR.
Briefly, a 20 ul reaction with 2X QuantiTect Multiplex PCR Master Mix, 4 uM (0.04 ul
of 100 uM) forward primer, 4 uM (0.04 ul of 100 uM) reverse primer, 4 uM (0.04 ul of
100 uM) probe were used. RNAse-free water was used to bring the final volume of each
reaction to 20 ul. 0.2 ul of DNA template was used in each 20 ul reaction. See Table 5 for
reaction setup. Each reaction included primer-probe sets specific for wildtype sequence
of the BRAF gene (this sequence was in an exon that is not known to harbor any
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mutations) and the BRAF(V600E) mutation (Figure 8 and Table 6). Table 7 outlines the
cycling conditions.
The presence of wild type BRAF was used as an internal control for the qPCR reaction.
Dilutions of 1:1, 1:10, 1:100, 1:250 of the BHT-101 cell line were used for standard
curve generation. ASH-3 cell line was used as negative control. Baseline was determined
based on the negative control. Cycle threshold (Ct) was determined where the
amplification plot crosses the baseline. Each sample was done in duplicates –
amplification plots of duplicates were averaged and a single curve was generated to
determine the Ct (Figure 9). Each sample was repeated at least twice. Ct for each sample
was then used to determine the amount of BRAF and BRAF(V600E) mutation using the
standard curve (Figure 10). The relative amount of BRAF(V600E) was calculated by the
following formula: BRAF(V600E ) / BRAF WT % = [V600E] / [WT] x 100. Selected
samples which were positive and negative for BRAF(V600E) mutation were sent for
Sanger sequencing to confirm the qPCR findings.

2.6 Statistical Analysis
Statistical Analysis was done using SPSS. Student’s t-test was done to compare preoperative and post-operative BRAF(V600E) ctDNA. Fischer’s exact test was used to
determine the association between detectable BRAF(V600E) ctDNA in preoperative
plasma samples and pathologic characteristics.
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3

Results

3.1 Patient Characteristics

A total of 61 patients were recruited. 55 (90.2%) patients were being considered for
surgery and six (9.8%) patients were being considered for iodine radiation therapy for
locoregional recurrence and were being considered for iodine radiation therapy. 21
(34.4%) were males and 40 (65.6%) were females. Of those 55 patients who underwent
surgery, final pathology of the thyroid nodules showed 13 (21.3%) were benign, 26
(42.6%) were classical PTC, 13 (21.3%) were non-classical PTC, 3 (4.9%) were FTC.
See Table 8 for baseline patient characteristics and final pathology of the index nodule.

Of those 55 patients with preoperative samples and being considered for surgery,
postoperative samples were obtained from 37 patients (67.3%). 12 (32.4%) were males
and 26 (67.6%) were females. Final pathology of the corresponding index thyroid nodule
showed 9 (21.6%) were nodular hyperplasia, 18 (48.6%) were classical PTC, 8 (21.6%)
were non-classical PTC, 3 (8.1%) were FTC. See Table 9 for paired preoperative and
postoperative patient characteristics and final pathology of the index nodule.
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3.2 BRAF(V600E) detection in preoperative samples in
patients with thyroid nodules

A total of 9/61 (14.8%) patients had detectable BRAF(V600E) in the preoperative plasma
samples (Figure 11). In patients with final diagnosis of nodular hyperplasia, 0/13 (0%)
patients had detectable BRAF(V600E) ctDNA in the preoperative plasma samples. In
patients with final diagnosis of classical PTC, 8/26 (30.8%) patients (patients 1, 6, 39, 40,
41, 42, 57, 63) had detectable BRAF(V600E) ctDNA in the preoperative plasma samples.
In patients who had underwent previous thyroidectomy and had a metastatic locoregional
recurrence of classical PTC, 0/2 (0%) patients had detectable BRAF(V600E) ctDNA in
the preoperative plasma samples. In patients who had underwent previous thyroidectomy
and had a metastatic locoregional recurrence of non-classical PTC, 1/4 (25%) patients
(patient 26) had detectable BRAF(V600E) ctDNA in the preoperative plasma samples.

3.3 Ability of BRAF(V600E) ctDNA to detect classical
papillary thyroid cancer

Using the pathologic diagnosis of the index thyroid nodule as the standard, presence of
BRAF(V600E) ctDNA in preoperative plasma samples was used to differentiate between
classical PTCs and benign thyroid nodules (Table 10). All the patients with detectable
BRAF(V600E) ctDNA had classical PTCs and none of the benign thyroid nodules had
detectable BRAF(V600E) ctDNA. This was statistically significant (p < 0.05).
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3.4 BRAF(V600E) detection before and after surgery in
patients with thyroid nodules

37 patients were followed post-operatively with an additional blood draw at one month
follow up. 6/37 (16.2%) patients had detectable BRAF(V600E) ctDNA in preoperative
plasma samples and all of them decreased postoperatively (p-value < 0.05), with five
patients having non-detectable BRAF(V600E) postoperatively (Figure 12).

The results were further analyzed based on the final histology of the index thyroid
nodule. None of the patients 0/8 (0%) with a final diagnosis of nodular hyperplasia had
detectable BRAF(V600E) ctDNA (Figure 13). 6/18 (33.3%) patients with a final
diagnosis of classical PTC had detectable BRAF(V600E) ctDNA and they all decreased
post-operatively (Figure 14) (p-value < 0.05). None of the patients with final diagnosis of
non-classical PTC - 0/8 (0%) (Figure 15) and FTC - 0/3 (0%) (Figure 16) had detectable
BRAF(V600E) ctDNA.

3.5 Correlation of BRAF(V600E) ctDNA with classical PTC
thyroid cancer staging

5/6 (83.3%) patients with detectable preoperative BRAF(V600E) ctDNA and final
diagnosis of classical PTC had higher T-stage (T3) compared to 1/6 (16.7%) patient had a
lower T-stage disease. This was not statistically significant (p-value > 0.05) (Table 11).
No association was noted with detectable levels of BRAF(V600E) ctDNA and nodal
metastases and extra-thyroidal extension (ETE) (p > 0.05).
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3.6 Detection of BRAF(V600E) in FFPE samples and
concordance with the presence of BRAF(V600E) ctDNA in
preoperative plasma samples

To assess the concordance between preoperative BRAF(V600E) ctDNA and
BRAF(V600E) mutational status of the index thyroid nodule, FFPE samples were
obtained and mutational status for BRAF(V600E) was determined (see Table 12). In
patients with final diagnosis of nodular hyperplasia: 8/8 (100%) did not have
BRAF(V600E) mutation in both FFPE and preoperative ctDNA samples. In patients with
final diagnosis of classical PTC: 4/18 (22.2%) patients had detectable BRAF(V600E)
mutation in both FFPE and preoperative plasma ctDNA samples (see Figure 17), 3/18
(16.7%) did not have BRAF(V600E) mutation in both FFPE and preoperative ctDNA
samples, 9/18 (50%) patients had BRAF(V600E) mutation in FFPE sample but not in the
preoperative plasma sample, and 2/18 (11.1%) patient had BRAF(V600E) mutation in
preoperative ctDNA plasma sample but not in the FFPE sample.
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4

Discussion

The results of this study indicate that ctDNA may have a role in diagnosing thyroid
cancer and its surveillance. US-FNAB is highly accurate in ruling out thyroid cancer in
low risk biopsies and ruling in cancer high risk categories (suspicious and positive for
malignancy). The specificity decreases in the indeterminate/intermediate group (Table 2).
Tests assessing the molecular profile of the thyroid nodules are available. However,
financial considerations as well as the necessity to send samples to a central repository is
a major barrier for these tests.50,60 Additionally patients continue to require follow up USFNAB on regular intervals. Moreover these tests would not be helpful in tumor
surveillance.

BRAF(V600E) was chosen for this pilot study as it is the most common genetic alteration
noted in PTCs and PTCs is the most common type of well-differentiated thyroid cancer.41
There have been varying reports of detection of BRAF(V600E) ctDNA in plasma of
patients with thyroid cancer ( Table 14 lists relevant studies). Bettegowda et al. attempted
to detect ctDNA in a multitude of tumor types, however only 4 patients in their study
(1%) had thyroid cancer.69 Moreover the mutations detected were all in different genes or
codons. Pupilli et al. studied 19 patients with thyroid cancer with pre-operative and postoperative blood testing. They found that 12/17 (71%) of patients had non-detectable
BRAF(V600E) ctDNA post-operatively and the other 5 patients had detectable levels
post-operatively but they were significantly lower compared to the pre-operative levels.77
Cradic et al. reported BRAF(V600E) ctDNA in 20 (11.6%) of the 173 thyroid cancer
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patients correlating with the presence of active disease at the time of the blood draw.78
Chuang et al. found that 3/14 (36%) of patients with PTC had BRAF(V600E) ctDNA.79
Kim et al. found BRAF(V600E) ctDNA in only 6.1% of the patients (3/49) with all three
patients having lateral lymph node or lung metastasis.80 Zane et al. reported
BRAF(V600E) ctDNA in 0% of the patients (0/181) as they were unable to analyze
ctDNA.81

We successfully detected BRAF(V600E) ctDNA in 9/61 (14.8%) patients with thyroid
nodular disease selected for surgery. Comparing the paired plasma samples, overall 6/37
(16.2%) had detectable BRAF(V600E) ctDNA with significant decline in all six patients
post-operatively. 0/8 (0%) patients with nodular hyperplasia had detectable
BRAF(V600E) preoperative plasma ctDNA, and the levels were non-detectable
postoperatively. Based on the molecular profiling reported by the TCGA group, we
decided to further classify the PTCs into classical and non-classical PTCs. 6/18 (33.3%)
classical PTC patients had detectable BRAF(V600E) preoperative plasma ctDNA – with
five patients having non-detectable BRAF(V600E) ctDNA levels post-operatively, while
one of the patients had a significant decline but remained detectable. This patient had
undergone total thyroidectomy, right central neck dissection and right neck dissection for
this disease. Intra-operatively, recurrent laryngeal nerve was encased in tumor and had
positive margins on the final pathology. Additionally, this patient had undergone SPECT
CT after his radioactive iodine treatment which showed two focal areas of uptake within
the thyroid bed suggesting residual disease. Thus drop in the BRAF(V600E) ctDNA
levels postoperatively may have an important role in cancer surveillance.
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In our study, we found that 0/8 (0%) patients with nodular hyperplasia on final pathology
had BRAF(V600E) ctDNA. Previous reports have suggested that up to 5.4% of thyroid
nodules determined to be benign on FNA can harbor BRAF(V600E) mutations, and when
combined with 2 or more high risk ultrasound features 88% are malignant on final
pathology.82 It has been speculated that these BRAF(V600E) positive “benign” thyroid
nodules may in fact be pre-malignant and would eventually turn malignant.83
Additionally, although pathology is the gold standard sampling error cannot be
discounted. During tissue processing only representative samples are typically obtained
especially in larger thyroid nodules and thus it is plausible that foci of cancer maybe
missed resulting in under-diagnosis of cancer. Patient 42 was initially diagnosed as
benign thyroid nodule on final pathology specimen, however after the study results
indicated that the patient had detectable BRAF(V600E) ctDNA in preoperative plasma
samples and subsequent decline in the levels after surgery, the pathology specimen was
reviewed and was diagnosed with classical PTC. This was confirmed with the HMBE-1
immunostaining as well.

Although our results were not statistically significant, there was a trend with correlation
of BRAF(V600E) ctDNA with T-stage.; no correlation with ETE or nodal metastasis was
noted. We speculate that with increased sample size all three of these poor pathologic
indicators (T-stage, ETE and nodal metastases) would all be associated with
BRAF(V600E) ctDNA. BRAF(V600E) mutation in PTC has been shown to correlate with
poorer prognosis.84 Tufano et al. included 14 studies in their meta-analysis to assess the
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prognosis of PTC in the presence of BRAF(V600E).85 Risk ratios in BRAF(V600E)
positive patients were 1.93 for PTC recurrence, 1.32 for lymph node metastasis, 1.71 for
ETE, 0.95 for distant metastasis and 1.70 for advanced stage AJCC III/IV. It is
conceivable that patients with BRAF(V600E) ctDNA can be treated newly developed
BRAF(V600E) inhibitors such PLX4720, PLX4032 and sorafenib86-88.
To assess the utility of BRAF(V600E) ctDNA in distinguishing benign versus malignant
thyroid pathology, BRAF mutational status in the FFPE index thyroid nodule was
assessed. 4/6 (66.7%) classical PTC patients who had detectable BRAF(V600E) ctDNA
also had BRAF(V600E) mutation in the FFPE samples and 2/6 (33.3%) patients had FFPE
samples with no BRAF(V600E) detectable in FFPE but present in ctDNA.. Chuang et al.
reported 3/5 (60%) patients who had detectable BRAF(V600E) ctDNA compared to the
corresponding FFPE tissue.79 Cradic et al. in their study reported one (11.11%) patient
out of nine having detectable BRAF(V600E) ctDNA while the corresponding FFPE
sample was negative for BRAF(V600E).78 Although 11 more patients had detectable
BRAF(V600E) ctDNA their FFPE status was not known. Pupilli et al. also had 3/9
(33.3%) patients who had detectable BRAF(V600E) ctDNA but did not have
BRAF(V600E) mutation in the corresponding FFPE tissue.77 In contrast to our study, the
concordance between detectable BRAF(V600E) ctDNA and FFPE BRAF(V600E)
mutational status was statistically significant.77 In our study, 2/6 (33.3%) patients with
detectable BRAF(V600E) in the FFPE samples but not in ctDNA. Sampling error could
have affected the inability to detect BRAF(V600E) in the FFPE samples, resulting in poor
correlation of circulating and primary tumor BRAF(V600E) status observed in our study.
Thyroid cancer is often a multi-focal disease with tumor heterogeneity. It has been
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demonstrated that BRAF(V600E) can be acquired as a secondary change during tumor
progression or it might be limited to subclone or separate focus in a multifocal tumor.83,89
As previously mentioned, sampling error was noted in one of our samples; patient 42
who was initially diagnosed with benign nodular hyperplasia on pathology but after
detectable BRAF(V600E) ctDNA and review of the pathology, a focus of HBME-1
immunostain positive classical PTC was noted. It is also likely that the index nodule may
be BRAF mutant but does not happen to shed significant BRAF(V600E) DNA due to
biological factors including tumor size, invasion and nodal metastases resulting in
negative ctDNA levels. Additionally it is important to remember that BRAF(V600E)
ctDNA can be positive in plasma in other malignancies including melanoma, lung cancer
and colorectal cancer.43,69 The fact that the levels declined to non-detectable levels in our
study in that patient suggest that the source of the BRAF(V600E) ctDNA was in fact
thyroid tissue.

5

Conclusion and Future Directions

In summary, our study shows that BRAF(V600E) ctDNA can differentiate between
malignant classical PTC thyroid cancer and benign nodules. Postoperative decline in
BRAF(V600E) ctDNA suggests its utility as a potential marker of surveillance marker in
a subset of thyroid cancers. Further work is needed to delineate its utility to identify
cancers with higher T-stage, ETE and nodal metastasis.
We are continuing to recruit more patients to increase the power of the study. Next
generation sequencing (NGS) is a newer technology with ability to detect point
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mutations, copy number variations and translocations. Ion-Torrent NGS platform will be
used to increase the sensitivity of the detection in. Current study only included
BRAF(V600E) however a host of additional driver mutations including point mutations,
copy number variations and translocations have been identified in thyroid cancer.41 NGS
will provide a platform to include an expanded panel of genes thus increasing the
coverage of mutations.
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Appendices

Appendix A: Figures

Figure 1: Age-standardized incidence rates (ASIR) for thyroid cancer in males and
females in Canada, 1986 – 2015. Data from 2011 to 2015, represented by dashed lines is
predicted.

Data from Canadian Cancer Society's Advisory Committee on Cancer Statistics5
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Figure 2: Different types of thyroid cancers. Thyroid gland is made of two cell types –
follicular cells and parafollicular cells. Majority of the thyroid cancers arise from the
follicular cells and papillary thyroid cancer is the most common type of thyroid cancer.

Modified from Caria and Vanni 13
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Figure 3: Algorithm for the evaluation of patients with one or more thyroid nodules.
Patients initially undergo characterization of the thyroid nodule as well as their thyroid
function status. Patients then undergo FNA. Further management of thyroid nodule
depends on the results of the FNA.

Modified from American Thyroid Association Guidelines Taskforce on Thyroid, et al. 16
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Figure 4: Proposed model of thyroid carcinogenesis. Three distinct pathways are
proposed for neoplastic transformation and proliferation of thyroid follicular cells: hyperfunctioning follicular thyroid adenoma, FTC and PTC. Most poorly differentiated and
undifferentiated thyroid carcinomas are thought to arise from pre-existing welldifferentiated thyroid carcinomas through additional genetic events.

Modified from Kondo, et al. 15
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Figure 5: Publications of ctDNA in Pubmed. There has been a recent explosion of
publications investigating ctDNA. Y-axis represents number of publications. X-axis
represents years.
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Figure 6: Important studies investigating cfDNA.

Modified from Schwarzenbach, et al. 72
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Figure 7: Sources of cell free nucleic acids include necrosis, apoptosis and secretion by
tumor and macrophages. These can then be detected in blood.

Modified from Schwarzenbach, et al. 72

43

Figure 8: qPCR primers were designed for non-mutated conserved BRAF region and
BRAF(V600E) mutation. The non-mutated conserved BRAF region was used as an
internal control of the qPCR reaction.
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Figure 9: Example of qPCR amplification plot of BRAF(V600E) with BHT-101 DNA
standards and patient ctDNA sample. ASH-3 cell line DNA was used as negative control.
Y-axis represents the fluorescence and X-axis represents the number of cycles. Baseline
was determined based on the negative control. Ct was determined where the
amplification plot crosses the baseline. Each sample was done in duplicates –
amplification plots of duplicates were averaged and a single curve was generated to
determine the Ct.
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Figure 10: Example of standard curve generation from the Ct value obtained from BHT101 standards. 1:1, 1:10, 1:100 and 1:250 dilution of BHT-101 was used as standard for
both non-mutated conserved BRAF region and BRAF(V600E). Y-axis represents Ct and
X-axis represents amount of DNA in nanograms. The relative amount of BRAF(V600E)
was calculated by the following formula: BRAF(V600E)/ BRAF WT % = [V600E] / [WT]
x 100.
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Figure 11: Detection of BRAF(V600E) in preoperative samples as determined by relative
amount of BRAF(V600E) (mean ±SE). 9/61 (14.8%) patients had detectable
BRAF(V600E) ctDNA. Y-axis represents average preoperative BRAF(V600E) /BRAF

A v g P re o p B R A F (V 6 0 0 E ) / B R A F W T %

wildtype percentage. X-axis represents individual patients.

125

100

75

50

25

0
01

6

10

20

26

30

40

P a t ie n t N u m b e r

50

57 60 63

70

47

Figure 12: BRAF(V600E) ctDNA detection as determined by relative amount of
BRAF(V600E) in patients with paired preoperative and postoperative samples (N = 37).
6/37 (16.2%) patients had detectable levels preoperatively and they all declined
postoperatively. Y-axis represents average BRAF(V600E) /BRAF wildtype percentage. Xaxis represents preoperative and postoperative samples. Each datapoint and
corresponding line represents an individual patient.
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Note: There is overlap of samples 40 and 42 in the graphic representation. Only means have been shown
for each sample. Patients with non-detectable ctDNA in either preoperative or postoperative samples are
not represented in this figure.
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Figure 13: BRAF(V600E) ctDNA detection as determined by relative amount of
BRAF(V600E) in paired preoperative and postoperative samples of patients with final
pathology suggestive of nodular hyperplasia (N = 8). 0/8 (0%) patients had detectable
levels preoperatively and they all declined postoperatively. Y-axis represents average
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and
postoperative samples. Each datapoint and corresponding line represents an individual
patient.
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Figure 14: BRAF(V600E) ctDNA detection as determined by relative amount of
BRAF(V600E) in paired preoperative and postoperative samples of patients with final
pathology suggestive of classical PTC (N = 17). 6/18 (33.3%) patients had detectable
levels preoperatively and they all declined postoperatively. Y-axis represents average
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and
postoperative samples. Each datapoint and corresponding line represents an individual
patient.
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Figure 15: BRAF(V600E) ctDNA detection as determined by relative amount of
BRAF(V600E) in paired preoperative and postoperative samples of patients with final
pathology suggestive of non-classical PTC (N = 8). 0/8 (0%) patients had detectable
levels preoperatively and they remained undetectable postoperatively. Y-axis represents
average BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and
postoperative samples. Each datapoint and corresponding line represents an individual
patient.
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Figure 16: BRAF(V600E) ctDNA detection as determined by relative amount of
BRAF(V600E) in paired preoperative and postoperative samples of patients with final
pathology suggestive of FTC (N = 3). 0/3 (0%) patients had detectable levels
preoperatively and they remained undetectable postoperatively. Y-axis represents average
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and
postoperative samples. Each datapoint and corresponding line represents an individual
patient.
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Figure 17: Concordance between FFPE samples and BRAF(V600E) ctDNA as
determined by relative amount of BRAF(V600E) (mean ±SE) in paired preoperative and
postoperative samples of patients with final pathology suggestive of classical PTC. 4/6
(66.6%) patients had detectable BRAF(V600E) ctDNA and corresponding BRAF(V600E)
in the FFPE samples. Y-axis represents average BRAF(V600E) /BRAF wildtype
percentage. X-axis represents each individual patient.
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Appendix B: Tables
Table 1: Clinical features of different types of thyroid cancer.

Sex ratio
Age Lymph-node Distant Survival rate
(female:male) (years) metastasis metastasis (5 year)

Tumour type

Prevalence

Papillary thyroid
carcinoma

85–90%

2:1–4: 1

20–50

<50%

5–7%

>90%

Follicular thyroid
carcinoma

<10%

2:1–3: 1

40–60

<5%

20%

>90%

0.4:1–2.1: 1

50–60

30–80%

30–80%

50%

Poorly differentiated
rare–7%
thyroid carcinoma
Undifferentiated
thyroid carcinoma

2%

1.5: 1

60–80

40%

20–50%

1–17%

Medullary thyroid
carcinoma

3%

1:1–1.2: 1

30–60

50%

15%

80%

Modified from Kondo, et al. 15
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Table 2: FNAB results based on Bethesda Thyroid Nodule System

Risk Category

Low

Indeterminate

Bethesda

Predicted
Risk of
Malignancy
(%)a

Malignancy
LHSC
Rate in
Malignancy Recommendations
Literature
Rate (%)c
(%)b

Nondiagnostic/
Unsatisfactory

1–4

16.8

13

Repeat U/S guided
FNAB

Benign

0–3

3.7

3

Follow

13 – 50

Repeat
FNAB/Close
followup

20 – 40

Close followup or
diagnostic hemithyroidectomy

80 – 98

Total
thyroidectomy

FLUS/AUS

5 – 15

15.9

Intermediate

FN/SFN

15 – 30

26.1

60 – 75

75.2

High

Suspicious for
malignancy
Malignant

97 – 99

98.6

a – 32, b - data primarily from 32,90-94, c – unpublished
LHSC – London Health Sciences Centre, FLUS – Follicular Lesion of Unknown Significance, AUS –
Atypia of Unknown Significance, FN – Follicular Neoplasm, SFN – Suspicious for Follicular Neoplasm (or
Hurthle Cell Neoplasm)
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Table 3: Genetic alterations in different types of thyroid cancers.

Genetic

Well-differentiated

alteration

thyroid carcinoma

RET
rearrangement
BRAF mutation
BRAF
rearrangement
NTRK1
rearrangement
RAS mutation
PPARG
rearrangement
CTNNB1
mutation
TP53 mutation

Poorly
differentiated
thyroid carcinoma

Undifferentiated
thyroid carcinoma

PTC

FTC

13–43%

0%

0–13%

0%

29–69%

0%

0–13%

10–35%

1%

Unknown

Unknown

Unknown

5–13%

Unknown

Unknown

Unknown

0–21%

40–53%

18–27%

20–60%

0%

25–63%

0%

0%

0%

0%

0–25%

66%

0–5%

0–9%

17–38%

67–88%

Modified from Kondo, et al. 15
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Table 4: Clinical applications of ctDNA. ctDNA can be used for diagnosis of disease,
predict response to treatment and prognostication by identifying early recurrence and
determining tumor burden.

Application
Early detection
Diagnostic
Monitoring of minimal residual disease
Assessment of molecular heterogeneity of overall disease
Monitoring of tumor dynamics
Predictive

Identification of genetic determinants for targeted therapy
Evaluation of early treatment response
Assessment of evolution of resistance in real time
Identification of high risk of recurrence

Prognostic
Correlation with changes in tumor burden

Modified from Heitzer, et al. 95
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Table 5: qPCR reaction setup

Component

Volume

Final Concentration

10 ul

1x

2x QuantiTect Multiplex PCR
Master Mix
0.4 uM forward primer
20x primer-probe mix 1

0.04 ul

0.4 uM reverse primer
0.4 uM probe
0.4 uM forward primer

20x primer-probe mix 2

0.04 ul

0.4 uM reverse primer
0.4 uM probe

RNase-free water

9.56 ul

Template DNA

0.2 ul

Total reaction volume

20 ul
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Table 6: qPCR Primer and Probe Sequences

Gene
BRAF non-mutated
exon

BRAF(V600E)

Primer/Probe Sequences
Forward

5’-TAGGTGATTTTGGTCTAGCTACCGA

Reverse

5’-GGATCCAGACAACTGTTCAAACTG

Probe

5’-[JOE]GAATCTCGATGGAGTGGGTC

Forward

5’-GATGCACTCCAACAAAGAGAACAA

Reverse

5’-GGTATCCATTGATGCAGAGCTAGA

Probe

5’-[ROX]TCTCTGGGGAACGGAACTGA
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Table 7: qPCR Cycling Conditions

Step

Time

Temperature (°C)

PCR initial activation step

15 min

95

Denaturation

1 min

94

Annealing/extension

1 min 30 sec 62

Number of cycles

40x

60

Table 8: Baseline patient characteristics and final pathology of the index nodule.

Preoperative Samples = 61
Males

21 (34.4%)

Females

40 (65.6%)

Benign

13 (21.3%)

PTC, classical

26 (42.6%)

PTC, non-classical

13 (21.3%)

FTC

3 (4.9%)

Metastatic PTC, classical

2 (3.3%)

Metastatic PTC, non-classical

4 (6.6%)

Pathology

61

Table 9: Paired preoperative and postoperative patient characteristics and final pathology
of the index nodule.

Paired Samples = 37
Males

12 (32.4%)

Females

25 (67.6%)

Benign

8 (21.6%)

PTC, classical

18 (48.6%)

PTC, non-classical

8 (21.6%)

FTC

3 (8.1%)

Pathology
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Table 10: Detection of BRAF(V600E) in benign and classical PTC in preoperative
plasma ctDNA samples.

Benign

Classical PTC

0

8

p-valuea

BRAF(V600E)
ctDNA positive

p < 0.05

BRAF(V600E)
ctDNA

13

18

negative
a - Fischer’s exact test was used to assess for statistical significance.
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Table 11: Correlation of BRAF(V600E) ctDNA and pathologic T-stage, N-stage and ETE
in patients with classical PTC patients.

ctDNA positive

ctDNA negative

Low T-stage

1

7

High T-stage

5

5

0

1

6

1a

3

2

1b

2

4

Absent

2

7

T-stageb

N-stage

p-valuea

p > 0.05

p > 0.05

p > 0.05

ETE
Present

4

5

a - Fischer’s exact test was used to assess for statistical significance.
b – Low T-stage was defined to be T1 and T2. High T-stage was defined to be T3 and T4.
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Table 12: Concordance between the mutational status of BRAF(V600E) in the FFPE
index thyroid nodule and preoperative BRAF(V600E) ctDNA based on histology.

FFPE positive

FFPE negative

Nodular

ctDNA positive

0

0

Hyperplasia

ctDNA negative 0

8

4

2

ctDNA negative 9

3

ctDNA positive
PTC, classical
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Table 13: Concordance between the mutational status of BRAF(V600E) in the FFPE
index thyroid nodule and ctDNA. Numbers in each cell represent the total of benign and
classical PTC samples.
FFPE positive

FFPE negative

ctDNA positive

4

2

ctDNA negative

9

11
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Table 14: Comparison of findings in various studies published on ctDNA in thyroid
cancer.
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Appendix C: TNM Classification System for
Differentiated Thyroid Carcinoma
T1
T2
T3
T4a
Tb
Tx
N0
N1a
N1b
Nx
M0
M1
Mx
Stages

Definition
Tumor diameter 2 cm or smaller
Primary tumor diameter >2 to 4cm
Primary tumor diameter >4 cm limited to the thyroid or
with minimal extrathyroidal extension
Tumor of any size extending beyond the thyroid capsule
to invade subcutaneous soft tissues, larynx, trachea,
esophagus, or recurrent laryngeal nerve
Tumor invades prevertebral fascia or encases carotid
artery or mediastinal vessels
Primary tumor size unknown, but without extrathyroidal
invasion
No metastatic nodes
Metastases to level VI (pretracheal, paratracheal, and
prelaryngeal=Delphian lymph nodes)
Metastasis to unilateral, bilateral, contralateral cervical
or superior mediastinal nodes
Nodes not assessed at surgery
No distant metastases
Distant metastases
Distant metastases not assessed
Patient age < 45 years

Stage 1
Stage II
Stage III

Any T, any N, M0
Any T, any N, M1

Stage IVa

Stage IVb
Stage IVc
Modified from Edge and American Joint Committee on Cancer. 96

Patient age 45 years or
older
T1, N0, M0
T2, N0, M0
T3, N0, M0
T1, N1a, M0
T2, N1a, M0
T3, N1a, M0
T4a, N0, M0
T4a, N1a, M0
T1, N1b, M0
T2, N1b, M0
T3, N1b, N0
T4a, N1b, M0
T4b, Any N, M0
Any T, Any N, M1
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Start Date: 10/02/2014
End Date: 31/08/2018
Keywords: thyroid cancer,biomarkers,circulating tumor DNA,screening test

Project Members
Principal Investigator

Prefix: Dr.
Last Name: Nichols
First Name: Anthony
Affiliation: Schulich School of Medicine and Dentistry\Otolaryngology
Rank: Assistant Professor
Gender: Male
Email:
Phone1:
Phone2:
Fax:
Mailing Address:
Institution:
Country:
Comments:

Others

Rank

Last
Name

First
Name

Schulich School of Medicine and
Dentistry\Imaging
Schulich School of Medicine and
Macneil Danielle
Dentistry\Otolaryngology
Schulich School of Medicine and
Van Uum Stan
Dentistry\Medicine-Dept of
Schulich School of Medicine and
Fung
Kevin
Dentistry\Oncology
Barrett
John
Health Sciences\Communication
Theurer Julie
Sciences & Disorders
Rachinsky Irina

Lecturer

Adjunct
Professor

Affiliation

Role In
Project
Co-Investigator
Co-Investigator
Co-Investigator
Co-Investigator
Co-Investigator
Co-Investigator
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Associate
Professor
Associate
Professor
Research
Assistant
Resident

Yoo

John

Kwan

Keith

Partridge Allison
Patel

Krupal

Schulich School of Medicine and
Dentistry\Otolaryngology
Schulich School of Medicine and
Dentistry\Pathology
Schulich School of Medicine and
Dentistry\Medicine-Dept of
Schulich School of Medicine and
Dentistry\Otolaryngology

Co-Investigator
Co-Investigator
Research
Support Staff
Student

Common Questions
1. Registration Information

#

Question
Answer
Do you confirm that you have read the
above information and that based on
1.1
Yes
that information you are completing the
correct form?
Has this study been submitted to any
other REB? If yes, please include the
1.2
No
approval letter (or relevant
correspondence).
If YES is selected in question 1.2
1.3 above, please indicate where this
project has been submitted and when.
Indicate the funding source for this
1.4 study or if there is no funding simply Self-funded
indicate "None".
If you have indicated a funding source
in question 1.4 above, please specify
Translational Head and Neck Cancer
1.5 the name of the funding source selected
Research Fund (philanthropic funds)
as well as the title of the grant and if
applicable the ROLA number.
Is this a sequel to previously approved
1.6
No
research?
If YES is selected in question 1.6
1.7 above, what is the REB number and
what are the differences?
1.8 Is this a student project?
Yes - Resident/Fellow
1.9 Is this a multi-site study?
No
If YES has been selected in question
1.10 1.9 above, name the lead site and
project leader for the study. If the study
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is administered by a Coordinating or
Contract Research Organization (CRO)
provide the name and contact
information.
Head and Neck Surgeons (involved in
patient recruitment, consent, coordinating
Please list the names of ALL Local
blood draws) -John Yoo, Kevin Fung,
(Western affiliated) team members who Anthony Nichols, Danielle MacNeil,
are working on this project. Please
Krupal Patel Pathologists (responsible for
ALSO list their ROLE in the project, reviewing the thyroid pathology and
i.e. what exactly is it that the team
obtaining punch biopsies from focuses of
1.11
member will do in this study? Please tumor) -Bret Wehrli and Keith Kwan Postsee the “i” for this question for
Doctoral Fellow (responsible for study
instructions on how to link their Romeo coordination, data interpretation). -Julie
accounts to this form so they have
Theurer Scientists (responsible for study
access to it.
design, mutational detection, data analysis,
manuscript preparation) -John Barrett,
Anthony Nichols, Krupal Patel
Are the investigator(s) based at any of
the sites below or will the study utilize
any patient data, staff resources or
1.12 facilities within any of these sites?
LHSC - Victoria Hospital
(Please indicate all applicable sites and
read the associated notes found in the
blue information icon above)
If this form was started by a team
member, has the role of Principal
Investigator been changed to the
Faculty member who will hold this role
for the study? This is required for
Not Applicable – Principal Investigator is
1.13 review of your submission, and any
the one who started the submission form
forms submitted without this change
being made will be returned without
being reviewed. (The blue information
“i” has the instructions on how to
change the role of PI.)
Thyroid nodules are very common, and the
majority are benign. Nodules are typically
evaluated with a needle biopsy, however a
large proportion of the needle biopsies are
Please provide a lay summary of the
non-diagnostic and surgery is offered.
1.14
study (typically fewer than 5 lines).
Needle biopsies can also be very
uncomfortable for patients. A non-invasive
blood test that can differentiate between
benign and malignant thyroid nodules
would be of tremendous value to better
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guide the care of these patients. DNA that is
shed by the tumor into the blood stream can
be detected and serve as a screening test.
2. Methodology

#

Question

Outline the study rationale including
relevant background information and
2.1
justification. Cite references where
appropriate.

Answer
Thyroid nodules are extremely common,
and can be indentified in over 50% of the
population on ultrasounds. The first line of
investigation for these nodules is a fine
needle aspiration (FNA) biopsy, however a
significant fraction of FNA results are
indeterminate. These patients typically
undergo a hemithyroidectomy, however
only 15% of indeterminate biopsies prove
to be cancer. In addition, needle biopsies
can be very uncomfortable for patients,
particularly if multiple passes are needed.
Ideally a accurate non-invasive blood test
that can distinguish between benign and
malignant nodules would be of great utility.
Such a test would both avoid unnecessary
surgery in patients with benign disease and
guide surgeons towards total thyroidectomy
in patients with malignancy. Another
challenge in thyroid disease is the follow up
of thyroid cancer. Thyroglobulin is secreted
specifically from thyroid tissue. After
thyroidectomy, rising thryoglobulin levels
are useful to detect recurrence in the
majority of cases. However, small
remenants of thyroid tissue are let in situ
after thyroidectomy that result in an
elevated thyroglobulin level despite the
absence of residual cancer. More
troublesome is a small cohort of thyroid
cancer patients that become thyroglobulin
negative despite demonstrable recurrent
disease. Improved diagnostics would be
helpful to monitor this cohort. It has been
well established that cancers shed DNA that
can be detected in the bloodstream.
Mutations in oncogenes and tumor
suppressors that are found in cancers should
not be found in the body of healthy patients.
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Studies in other cancers have shown that the
detection of circulating tumor DNA
(ctDNA) in cancer patients can serve as a
ultra-sensitive test of disease status. Unlike
the majority of malignacies, the majority of
well differentiated thyroid cancers (~80%)
have either a specific fusion (RET/PTC or
PAX8/PPARgamma) or hotspot mutations
in well described oncogenes (RAS,
PIK3CA, BRAF). Thus a rather small panel
of mutations can be tested for in plasma
samples as a screening and surveillance test
for a large fraction of thyroid cancers.
Although well described in other cancers,
ctDNA has largely not been investigated in
thyroid disease with the exception of a pilot
study that evaluated only BRAF mutations
(PUBMED ID: 19850689).
1) To determine the ability to detect BRAF,
PIK3CA, RAS mutations and RET/PTC
Please provide a clear statement of the and PAX9/PPARgamma fusions in the
2.2 purpose and objectives of this project plasma of patients with thyroid nodules
(one page maximum).
using a real time PCR assay. 2) To
determine the reliability of ctDNA detection
with malignancy on final pathology.
Patients undergoing thyroid surgery with
benign, indeterminate and malignant needle
biopsies will be identified for study. Ten
mL of blood will be drawn at the time of
routine bloodwork preoperatively and at
one month, three month, six month and one
year follow-up with the surgeon after
surgery. An additional 10 ml of blood
sample will be collected immediately after
Describe the study design/methodology surgery once the specimen has been
2.3 and attach all supporting documents in removed. The blood will be centrifuged and
the attachments tab.
the plasma removed. DNA will be extracted
from the plasma and tested for mutations in
the previously mentioned mutations and
fusions by real-time polymerase reaction
(PCR). The cycle threshold difference
between the wild type and mutation specific
primers will be used to determine positivity.
Positive PCR assays pre and postoperatively will be compared to the results
of surgery. A subset of the thyroidectomy
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2.4

Indicate the inclusion criteria for
participant recruitment.

Considering your inclusion criteria
2.5 listed above, what is the basis to
exclude a potential participant?

If using patients, describe the usual
standard of care at the study site(s) for
2.6
this population (including diagnostic
testing, frequency of follow up visits).

Describe the study procedures and any
2.7 study specific testing that will be done,
outside of standard care.

samples (100) will be screened by a
pathologist. Area of tumor will be identified
and multiple 1mm cores (up to 5) will be
taken from the center of the tumor and
DNA will be extracted. The above
mentioned mutations and fusions will be
tested for by real-time PCR.
1) Age 18 or older 2) Scheduled to undergo
partial or total thyroidectomy for nodules
1) Previous cancer that is known to be
positive for one of the tested mutations (i.e.
melanoma which may contain BRAF
mutations).
All thyroidectomy patients undergo pre and
post-operative testing to assess thyroid
function (TSH, T3, T4), parathyroid levels
(PTH), and calcium levels. At the very least
this occurs at initial consultation and at the
follow up at ~3-4 weeks to discuss the
pathology. Thus the patient will be
undergoing a blood draw at these
appointments. The sample (10mL) for
mutational testing would be draw at the
same time using blood tubes provided by
the principal investigator, thus no additional
blood draws or hospital resources are
required for this study.
Blood and tumor mutational analysis by
real-time PCR will be tested. As this is not
done in a certified lab setting and the
significance of the findings are not yet
known, results will not be reported to the
patient.

How many participants over the age of
18 from London will be enrolled in
2.8
Up to 400.
your study? This includes hospital and
university sites within London.
How many participants under the age
of 18 from London will be enrolled in
2.9
0
your study? This includes hospital and
university sites within London.
How many participants over the age of
18 will be included at all study
2.10
Up to 400.
locations? (London + Other locations =
Total)
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How many participants under the age
of 18 will be included at all study
2.11
0
locations? (London + Other locations =
Total)
Mutational and fusion protein analysis will
be carried out by real-time PCR testing. Pre
Describe the method(s) of data
and post-operative mutational levels will be
2.12
analysis.
compared as will the presence of mutations
in patients with benign and malignant
thyroid nodules.
How will the results of this study be
2.13
Peer reviewed publication
made public?
If report to participants or other is
2.14
selected above, please explain.
No feedback will be provided as the
Briefly provide any plans for provision
significance of the mutation analysis is not
2.15 of feedback of results to the
yet determined and the testing is not carried
participants.
out in a certified lab.
Does this study include any use of
deliberate deception or withholding of
2.16
No
key information that may influence a
participant's performance or response?
If YES in question 2.16 above, describe
this process and justification including
2.17 how the participants will be debriefed
at some point. Please include the
debriefing script.
3. Risks and Benefits

#

Question
Answer
List any potential anticipated benefit to None other than potentially improving the
3.1
the participants.
care of future patients with thyroid disease.
Blood mutational testing may offer a noninvasive way to assess the risk of
malignancy in thyroid nodules. This may
help to avoid unnecessary surgery in
patients with benign nodules and identify
3.2 List the potential benefits to society.
patients that would benefit from total
thyroidectomy versus two step
thyroidectomy. This study may also lead to
a more accurate way to follow patients with
thyroid cancer.
List any potential risks to study
3.3
None.
participants.
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3.4

List any potential inconveniences to
daily activities.

None. All the additional blood samples
would be collected at the time of blood
draws needed for clinical care.

4. Recruitment and Informed Consent

#

Question
Answer
How will potential participants be
contacted and recruited? Select all that
Investigators will approach their own
4.1 apply. A copy of all recruitment tools
patients/students
that will be used must be included with
this submission in the attachments tab.
The investigators including the four
surgeons (Yoo, Nichols, Fung, MacNeil,
Patel (resident)) and three endocrinologists
(Morrison, Van Uum, Paul) will be
Please explain in detail your selection responsible for patient recruitment in clinic
4.2 from 4.1 and how it will be used to
preoperatively. The letter of information
recruit participants.
and consent will be used to provide a
description of the study to potential
subjects. Drs. Nichols, Barrett and Mymryk
will be responsible for the mutational
testing.
Which research team members will be
4.3
See above.
recruiting the potential participants?
Does the Principal Investigator have
Yes, the principal investigator will be
4.4 any relationship to the potential
recruiting subjects, some of which will be
participants?
his own patients.
Does the person recruiting the
participants have any relationship or
4.5
Yes
hold any authority over the potential
participants?
The majority of time, the person recruiting
If you have answered "Yes" to either participants will be the treating physician.
4.6
4.4 or 4.5, please explain here.
As this is a low/no risk study the chance of
harm is negligible.
What method of obtaining consent will
you use for participants? A copy of all
4.7
Written Consent
forms being used for obtaining consent
must be included with this submission.
If you are unable to obtain consent or
4.8 assent using one of the methods listed
above, please explain here.
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Indicate if you will be recruiting from
4.9 any of the following groups specifically Patients
for this study. (select all that apply)
Will minors or persons not able to
4.10 consent for themselves be included in No
the study?
If YES is selected in question 4.10
above, describe the consent process and
indicate who will be asked to consent
4.11 on their behalf and discuss what
safeguards will be employed to ensure
the rights of the research participant are
protected.
When the inability to provide an
informed consent is expected to be
temporary, describe what procedures
will be used to regularly assess capacity
and to obtain consent if the individual
Only patients able to consent at the time of
4.12 later becomes capable of providing
preoperative consultation will be recruited.
consent. Alternatively, if diminished
capacity is anticipated for the study
population, describe the procedure used
to assess capacity and obtain ongoing
consent.
List any anticipated communication
4.13
None
difficulties:
Describe the procedures to address any
4.14 communication difficulties (if
not applicable.
applicable):
Indicate what compensation, if any,
will be provided to subjects. For
example, reimbursement for expenses
incurred as a result of research,
4.15
none.
description of gifts for participation,
draws and/or compensation for time.
Include a justification for this
compensation.
5. Confidentiality and Data Security

#

Question
Answer
Are you collecting personal identifiers
5.1
Yes
for this study?
Identify any personal identifiers
5.2
Full name|Health card number|Date of birth
collected for this study.
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Patients will need to be followed to
determine if there is a difference in pre and
If you checked any of the personal
post operative mutational status and if
information in 5.2 above, please
serum mutational status correlates with the
5.3
explain and justify the collection of this tumor. This will require creation of a
identifier.
password protected secure database located
on a hospital network drive (S drive) behind
the hospital firewall.
Where will information collected as
University or Hospital network drive
5.4 part of this study be stored? (select all
(specify below)
that apply)
If you have indicated any of the
We will create a password protected secure
5.5 locations in question 5.4, please specify database stored on a hospital drive behind
here.
the hospital firewall.
If identifiable participant information is
stored on a hard drive or portable
5.6
Not applicable.
device, the device must be encrypted.
Describe encryption being used.
5.7 How will you record study data?
Data Collection Form|Other
Patient data will be immediately entered
If you select "Other" in 5.7, please
5.8
into the secure database on the network
explain why here:
server once an individual is recruited.
All identifying information will only be
Describe the coding system to protect stored in the secure database. Collected
5.9 identifiable information or explain why samples will be labelled with participant
the data must remain identifiable.
number only - i.e. #1, #2, #3, #4 and so on,
to maintain patient confidentiality/privacy.
Paper file (Required Protection: Locked
How will you store and protect the
cabinet in locked institutional
master list, signed original letters of
office)|Electronic file (local) (Required
5.10
information and consent documents or Protection: Password protected computer on
other data with identifiers?
a secure network behind institutional
firewalls - specify location)
Password protected secure database stored
If any options are selected above,
5.11
on a hospital drive behind the hospital
please provide the specific details here.
firewall.
How will you store and protect data
5.12
Not applicable.
without identifiers?
If you plan to de-identify the study
5.13 data, please describe the method of de- Not applicable.
identification.
For 5 years after the completion of the
5.14 How long will you keep the study data?
study.
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How will you destroy the study data
Delete the database.
after this period? (If applicable)
Does this study require you to send data
outside of the institution where it is
collected? This includes data taken off5.16 site for analysis. Please note that
No
Western/Robarts are considered off-site
locations for hospital/Lawson based
studies, and vice-versa.
5.17 Where will the data be sent?
Not applicable.
Does the data to be transferred include
5.18 personal identifiers? If yes, a data
No
transfer agreement may be necessary.
List the personal identifiers that will be
5.19
Not applicable.
included with the data sent off-site.
If you have answered yes to 5.18 please
5.20 indicate how the data will be
transmitted
Please specify any additional details on
5.21
data transmission below.
Will you link the locally collected data
5.22
No
with any other data sets?
If YES is selected in question 5.22
5.23
above, identify the dataset
If YES is selected in question 5.22
5.24 above, explain how the linkage will
occur.
If YES is selected in question 5.22
5.25 above, provide a list of data items
contained in the dataset.
Will the data be entered into a database
5.26
Yes
for future use?
If YES is selected in question 5.25
The data will be stored on a password
above, please specify where it will be protected database on a hospital server (S
5.27 stored, who the custodian will be, who Drive) behind the hospital firewall. Only
will have access to the database and
the study investigators will have access to
what security measures will be in place. the information.
Please list agencies/groups/persons
outside of your local research team who
5.28
Not applicable.
will have access to the identifiable data
and indicate why access is required.
Western University policy requires that
Yes, data will be kept for 5 years after
5.29 that you keep data for a minimum of 5
completion of the study.
years. Please indicate if you are
5.15
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keeping data in accordance to this
policy, otherwise please comment on
how your data retention will differ from
University policy and why. If you will
be archiving the data, please explain
why and how here.
6. Conflict of Interest

#

6.1

6.2

6.3

6.4

Question
Answer
Will any investigators, members of the
research teams, and/or their partners or
immediate family members function as No
advisors, employees, officers, directors
or consultants for this study?
Will any investigators, members of the
research team, and/or their partners or
immediate family members have a
direct or indirect financial interest
Yes
(including patents or stocks) in the
drug, device or technology employed in
this research study?
Will any investigators, members of the
research team, and/or their partners or
immediate family members receive any
Yes
personal benefit (apart from fees for
service) as a result of, or connects to
this study?
The results of this study may potentially
If YES is selected in any of the above,
lead to patents and a commercial product.
please describe the nature of the
We will take the appropriate steps within
conflict of interest and how all
the Western University policy if we wish to
conflict(s) of interest will be managed.
commercialize the findings.

7. Industry Sponsored Protocols

#
Question
7.1 Is this an industry sponsored protocol? No
Billing Information - Company
7.2
Institution:
7.3 Contact Person:
7.4 Email of Contact Person:
7.5 Street Address:
7.6 City:

Answer

80

7.7 Country:
7.8 Province/State:
7.9 Phone Number:
7.10 Fax:
Contract and/or protocol reference
7.11
number required:
Additional Sponsor Reference or
7.12
contact information:
Do you wish to apply for a REB
7.13 Administration Fee
Adjustment/Waiver?
If YES to question 7.13 above, provide
a brief written explanation indicating
how the funding will be used, who will
own the data or any intellectual
7.14
property arising from the agreement
and indicate if there are any restrictions
imposed upon the investigator by the
sponsor and, if so, what they are.
Do you agree to the Conditions for
7.15 Industry Funded Research
Investigators?
Do you agree to provide supporting
7.16 documents? (These can be added in the
attachments section)
8. Confirmation of Responsibility

#

8.1

8.2

8.3
8.4

Question
Answer
As the Principal Investigator I have read the Tri-Council Policy
Statement 2 and Western University's Guidelines on Research
Involving Human Subjects and agree to abide by the guidelines Yes
therein:
http://uwo.ca/research/ethics/health_sciences/d_guidelines.html
I attest that all Collaborators working on this Research Study
(co-investigators, students, post-docs, etc.) have reviewed the
Yes
protocol contents and are in agreement with the protocol as
submitted;
All Collaborators have read the Tri-Council Policy Statement 2
and Western University's Guidelines on Research Involving
Yes
Human Subjects and agree to abide by the guidelines therein;
The Collaborators and I will adhere to the Protocol and
Yes
Letter(s) of Information as approved by the REB;
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Should I encounter any changes or adverse events/experiences,
Yes
I will notify the REB in a timely manner.
If the Research Study is funded by an external sponsor, I will
not begin the Research Study until the contract/agreement has
8.6
Yes
been approved by the appropriate university, hospital, or
research institute official.
Have you exported a copy of this submission to Word using the
8.7 "Export to Word" button? Note that you will be unable to
Yes
submit future revisions if this is not done.
Letter(s) of
Have you uploaded the following documents, if applicable, to
Information and
8.8 the attachments tab? Incomplete submissions will be returned
Consent
without being reviewed.
Documentation
8.5

9. Confirmation of Responsibility - Student

#
Question
Answer
9.1 Is this a student project?
Yes
As the Student I have read the Tri-Council Policy Statement 2
and Western University's Guidelines on Research Involving
9.2
Yes
Human Subjects and agree to abide by the guidelines therein:
http://uwo.ca/research/ethics/health_sciences/d_guidelines.html
I will adhere to the Protocol and Letter(s) of Information as
9.3
Yes
approved by the REB;
I will notify the Principal Investigator as soon as possible if
9.4 there are any changes or adverse/experiences,
Yes
violations/deviations in regards to the Research Study.

Attachments
Description
Letter of Information and Consent

File Name
Thyroid Circulating Tumor REB
v10.docx
103985 - Nichols.pdf
Thyroid Circulating Tumor REB v20 with highlights.docx
Thyroid Circulating Tumor REB
v20.docx
Thyroid Circulating Tumor REB
v20.pdf
Data Collection Form - Detection of
Circulating Tumor DNA in Thyroid
Cancer.xls

Version
Date
22/06/2013
22/06/2013
25/09/2013
25/09/2013
25/09/2013
24/09/2013
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Thyroid Circulating Tumor
Pathology Approval (Received for
information only)

Thyroid Circulating Tumor Pathology
27/08/2013
Approval.PDF

103985 - Response letter to the
28/08/2013
concerns raised by HSREB.pdf
103985 - Response letter to the
28/08/2013
concerns raised by HSREB.doc
Data Collection Form - Detection of Data Collection Form - Detection of
Circulating Tumor DNA in Thyroid Circulating Tumor DNA in Thyroid
04/10/2013
Cancer
Cancer v20.xls
Thyroid Circulating Tumor REB
04/10/2013
v30.docx
Thyroid Circulating Tumor REB v30 04/10/2013
with highlights.docx
Recommendations
103985 - Nichols.pdf
26/07/2013
With updated LOI including
Thyroid Circulating Tumor REB v40 information about disclosure of
31/10/2013
with highlights.docx
results
With updated LOI including
Thyroid Circulating Tumor REB
information about disclosure of
31/10/2013
v40.docx
results
With updated LOI including
Thyroid Circulating Tumor REB
information about disclosure of
31/10/2013
v40.pdf
results
Nichols 103985.pdf
13/11/2013
103985 - with highlights.doc
103985.doc
(Received Dec 9/13) Inclusion of 40
103985.pdf
metastatic disease patients
Thyroid Circulating Tumor REB v50 with highlights.docx
Thyroid Circulating Tumor REB
v50.docx
Thyroid Circulating Tumor REB
v50.pdf
Thyroid Circulating Tumor REB v5.0 metastatic papillary thyroid cancer.pdf
Thyroid Circulating Tumor REB v5.0 metastatic papillary thyroid
17/09/2013
cancer.docx
Thyroid Circulating Tumor REB v6.0 09/02/2014
metastatic papillary thyroid cancer.pdf
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DOC021014-021020141545020002.pdf

10/02/2014
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Appendix E: Research Ethics Board Approval
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Appendix F: Letter of Information and Informed
Consent – Metastatic Thyroid Cancer Patients
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Appendix G: Letter of Information and Informed
Consent

90

91

92

Appendix H: List of Abbreviations

ASIR

Age Standardized Incidence Rate

AUS

Atypia of Unknown Significance

cfDNA

Cell free DNA

ctDNA

Circulating Tumor DNA

FNAB

Fine Needle Aspirate Biopsy

FLUS

Follicular Lesion of Unknown Significance

FN

Follicular Neoplasm

FTC

Follicular Thyroid Cancer

LHSC

London Health Sciences Centre

PTC

Papillary Thyroid Cancer

PCR

Polymerase Chain Reaction

SFN

Suspicious for Follicular Neoplasm (or Hurthle Cell Neoplasm)

TSH

Thyroid Stimulating Hormone

US

Ultrasound

US-FNAB

Ultrasound guided Fine Needle Aspirate Biopsy
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